Pulmonary fibrosis is a group of serious lung diseases that affect the respiratory system. Pulmonary fibrosis scars and thickens lung tissue. It impacts the connecting tissue in the lung and the

Nuformix said that it has published an international patent for its NXP004 asset, which could be used to treat a variety of illnesses. The UK pharmaceutical company said that NXP004

Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease that affects the tissue surrounding the air sacs, or alveoli, in your lungs. This condition develops when that lung

NXP002 is our lead asset and a potential novel inhaled treatment for idiopathic pulmonary fibrosis Repurposed new form of the drug tranilast, to be delivered in an inhaled formulation. Tranilast

Quotient Sciences, a UK-based firm that describes itself as a “drug development and manufacturing accelerator”, has integrated drug substance into its flagship Translational Pharmaceutics platform, uniting it with drug product

1. What is pulmonary fibrosis? In technical terms, fibrosis means thickening or scarring of the tissue. In this case, the normally thin, lacy walls of the air sacs in the